Further studies reported that KLC2-MT augmented signal transducer and activator of transcription 3 (STAT3) activation and nuclear accumulation in imatinib-treated CML cells. This evidence concerns the gene KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive.